Pharmaceutical Technology

FEBRUARY 10, 2023

On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5 This is not the first treatment to come with a high price tag.

Gene Therapy 263

Gene Therapy Marketing Gene Drugs 263

Pharmaceutical Technology

JUNE 21, 2023

CSL announced the first patient with haemophilia B has been treated with its recently approved gene therapy Hemgenix (etranacogene dezaparvovec). Hemgenix is the first and only gene therapy approved for haemophilia B. In the study, Hemgenix reduced or eliminated the need for prophylactic treatment in 94% of patients.

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

Drug Discovery World

MAY 22, 2023

But are these price tags a barrier to access? In the case of Hemgenix, the assurance behind the price point is that the drug would reduce long-term healthcare costs as patients would have fewer healthcare incidents and need fewer clotting treatments. million per dose.

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52

XTalks

NOVEMBER 24, 2022

In a pivotal approval, the US Food and Drug Administration (FDA) has given the nod to a new gene therapy called Hemgenix (etranacogene dezaparvovecfor) for the treatment of adults with the genetic blood disorder hemophilia B (congenital Factor IX deficiency). UniQure will manufacture Hemgenix at its Lexington, Massachusetts site.

Gene Therapy 52

Gene Therapy Gene FDA Approval Genetics 52

XTalks

NOVEMBER 30, 2022

The approval was awarded to CSL Behring’s Hemgenix, a single-dose gene therapy that delivers a working copy of the gene that codes for the Factor IX protein that is deficient, or made in insufficient amounts, in patients with Hemophilia B. Read the full articles here: Hemgenix Approved as First Gene Therapy for Hemophilia B.

Gene Therapy 52

Gene Therapy Life Science Gene FDA Approval 52

XTalks

DECEMBER 21, 2022

Hemgenix (etranacogene dezaparvovec) is for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently receive Factor IX prophylaxis therapy. Currently, CSL Behring’s one-dose Hemophilia B gene therapy Hemgenix holds the title at $3.5 Manufacturer: Ferring Pharmaceuticals A/S.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

XTalks

MARCH 22, 2023

Hemgenix (etranacogene dezaparvovec), developed by CSL Behring, is a gene therapy that allows patients with moderate-to-severe hemophilia to produce their own factor IX, a clotting factor important in controlling bleeding. Just last year, the FDA approved a one-time gene therapy treatment for hemophilia B priced at $3.5

Life Science 97

Life Science Drugs FDA Approval Vaccination 97